Application of streptococcus non-lactolyticus in preparation of products for preventing obesity

Abstract

The invention discloses application of streptococcus non-lactolyticus in preparation of products for preventing obesity, and belongs to the technical field of animal nutrition and feed science. According to the application disclosed by the invention, the streptococcus non-lactolyticus CCUG41503 is prepared into a bacterial solution with the concentration of 1 * 10 < 8 > CFU / mL, and the broiler chicken and obese mice are subjected to intragastric administration, so that the streptococcus non-lactolyticus CCUG41503 is found to be capable of reducing the abdominal fat percentage of the broiler chicken and the diameter and the area of fat cells, and also reducing the epididymal white fat weight of the obese mice and the diameter and the area of the fat cells. The result shows that the streptococcus lacticosus CCUG41503 has the fat reducing effect, and has wide applicability in multiple species.

Description

Technical Field

[0001] The present invention relates to the technical field of animal nutrition and feed science, and particularly to the application of Streptococcus dysgalactiae subsp. dysgalactiae in the preparation of products for preventing obesity. Background Art

[0002] At present, excessive fat deposition has become a major challenge in the fields of animal production and human health. In humans, the accumulation of visceral fat is considered a sign of obesity and is closely related to metabolic diseases such as type II diabetes, hypertension, and cardiovascular diseases. In livestock and poultry production, excessive abdominal fat deposition in broilers reduces feed utilization efficiency and increases production costs. In addition, it also increases the risk of metabolic diseases and affects the health and production sustainability of broilers. Therefore, reducing fat deposition is crucial for improving animal production efficiency and solving related human health problems.

[0003] Regarding the problem of fat deposition, the existing technologies mainly focus on nutritional regulation, genetic selection, and microbial intervention. Nutritional regulation includes the use of low-carbohydrate diets and functional additives, but such methods often have the disadvantages of long cycles and high costs, and may have a negative impact on the growth performance of animals. Genetic selection is carried out by selecting low-fat line varieties, and although certain progress has been made, due to the long breeding cycle, there are certain challenges in practical applications. Recent studies have shown that the microbiota plays an important role in regulating lipid metabolism, and some probiotics have shown potential application prospects in regulating fat metabolism. Therefore, as an emerging regulatory means, microbial intervention provides a new idea for solving the problem of excessive fat deposition. Summary of the Invention

[0004] The purpose of the present invention is to provide the application of Streptococcus dysgalactiae subsp. dysgalactiae in the preparation of products for preventing obesity to solve the problems existing in the above-mentioned prior art. The present invention uses broiler and obese mouse models to determine that Streptococcus dysgalactiae subsp. dysgalactiae CCUG41503 can be used as a functional probiotic to relieve fat deposition to prevent obesity and metabolic diseases.

[0005] To achieve the above purpose, the present invention provides the following solutions:

[0006] One of the technical solutions of the present invention is the application of Streptococcus dysgalactiae subsp. dysgalactiae in the preparation of products for preventing obesity.

[0007] Another technical solution of the present invention is a product for preventing obesity, comprising Streptococcus dysgalactiae subsp. dysgalactiae CCUG41503.

[0008] Based on the above technical solutions, the present invention has the following technical effects:

[0009] The present invention prepares Streptococcus dysgalactiae subsp. dysgalactiae CCUG41503 into a concentration of 1×108 The bacterial suspension of CFU / mL was used to intragastrically administer broiler chickens and obese mice. It was found that Streptococcus dysgalactiae CCUG41503 could reduce the abdominal fat rate, as well as the diameter and area of fat cells in broiler chickens. At the same time, it also reduced the epididymal white fat weight and the diameter and area of fat cells in obese mice. This indicates that Streptococcus dysgalactiae CCUG41503 has a fat-reducing effect and has broad applicability in multiple species. Brief Description of the Drawings

[0010] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can be obtained based on these drawings.

[0011] Figure 1 It is the H&E staining of the abdominal fat tissue of broiler chickens and the statistics of the diameter and area of fat cells. Among them, A is the anatomical diagram and H&E staining diagram of the abdominal fat tissue, B is the statistical chart of the diameter of fat cells, and C is the statistical chart of the cross-sectional area of fat cells.

[0012] Figure 2 It is the effect of intragastric administration of Streptococcus dysgalactiae CCUG41503 on the body weight and blood lipid content of obese mice. Among them, A is the body weight of mice, B is the average food intake, and C is the content of triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and glucose in serum.

[0013] Figure 3 It is the effect of intragastric administration of Streptococcus dysgalactiae CCUG41503 on the deposition of epididymal white fat in obese mice. Among them, A is the anatomical diagram and H&E staining diagram of the epididymal white fat tissue, B is the total fat weight, C is the total fat rate (total fat rate (%) = total fat weight / body weight × 100%), D is the weight of the epididymal white fat tissue, E is the epididymal white fat rate (epididymal white fat rate (%) = epididymal white fat weight / body weight × 100%), F is the statistical chart of the diameter of fat cells, and G is the statistical chart of the cross-sectional area of fat cells. Detailed Embodiments

[0014] Now, various exemplary embodiments of the present invention will be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, characteristics, and implementation schemes of the present invention.

[0015] It should be understood that the terms used in the present invention are only for describing specific embodiments and are not intended to limit the present invention. Additionally, for the numerical ranges in the present invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Each intermediate value within any stated value or stated range, as well as each smaller range between any other stated value or intermediate value within the stated range, is also included in the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0016] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although the present invention only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the documents. In case of conflict with any incorporated document, the content of this specification shall prevail.

[0017] Without departing from the scope or spirit of the present invention, various improvements and changes can be made to the specific embodiments of the present invention specification, which are obvious to those skilled in the art. Other embodiments obtained from the specification of the present invention are obvious to those skilled in the art. The specification and examples of this application are merely exemplary.

[0018] Regarding the use of "comprising", "including", "having", "containing", etc. herein, they are all open-ended terms, meaning including but not limited to.

[0019] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are all purchased from commercial channels or have been made public.

[0020] The embodiments of the present invention provide the use of Streptococcus lactolyticus in the preparation of a product for preventing obesity.

[0021] In some specific embodiments, the Streptococcus lactolyticus plays a role in reducing fat and preventing obesity by reducing the abdominal fat rate, body weight, and the contents of total cholesterol and triglyceride in the serum.

[0022] The embodiments of the present invention also provide a product for preventing obesity, comprising Streptococcus lactolyticus.

[0023] In view of the limitations of the prior art in the regulation of fat deposition, the present invention proposes a more efficient and feasible solution. Although current nutritional regulation methods (such as low-carbohydrate diets and functional additives) can reduce fat deposition to a certain extent, they have the defects of long regulation cycles, high production costs, and may have an adverse impact on animal growth performance. Although genetic breeding methods can cultivate low-fat line varieties, due to the long breeding cycle and limited genetic improvement efficiency, it is difficult to meet the actual production needs. In addition, as an emerging strategy, microbial intervention has shown potential regulatory effects on lipid metabolism, but existing research is still in its initial stage, and the screening of applicable strains and their specific mechanisms of action are not clear, which restricts its application in production. The purpose of the present invention is to overcome the deficiencies of existing methods, provide an efficient, low-cost, and feasible means of regulating fat deposition, optimize animal lipid metabolism, improve production performance, and reduce the risk of metabolic diseases related to fat deposition, thereby enhancing the sustainable development of livestock and poultry farming.

[0024] The Streptococcus dysgalactiae used in the present invention was purchased from Ningbo Mingzhou Biotechnology Co., Ltd., with the number CCUG41503 (https: / / www.ccug.se / strain? id=41503&s=0&p=1&sort=rel&collection=entire&records=25&t=41503).

[0025] Example 1

[0026] Effect of gavage with Streptococcus dysgalactiae on the growth performance and abdominal fat rate of broilers.

[0027] First, the Streptococcus dysgalactiae strain was activated to prepare a gavage bacterial suspension, and the specific method was as follows: Streptococcus dysgalactiae CCUG41503 was inoculated into BHI broth medium at a ratio of 2% (v / v), and continuously activated for three generations at 37 °C and then amplified. The amplified bacterial liquid was centrifuged at 4,000 rpm and 4 °C for 15 min, and the bacterial cells were washed twice with sterile PBS and centrifuged at 4,000 rpm and 4 °C for 15 min to collect the bacterial cells. Finally, it was diluted with sterile PBS to adjust the viable cell count to 1×10 8 CFU / mL for subsequent gavage of broilers and mice.

[0028] Two hundred 1-day-old Arbor Acres (AA) broiler chickens with similar body weights (half male and half female) were selected and randomly divided into a control group (CON) and a bacterial liquid gavage group (SA) using a single-factor completely randomized experimental design.

[0029] During the experiment, the broilers had free access to food and sufficient water and were immunized routinely. Starting from 14 days of age, the SA group was gavaged with 1×10 8The non-lactolytic Streptococcus CCUG41503 was gavaged at a dose of CFU / mL with 1 mL, and the CON group was gavaged with an equal amount of PBS every day.

[0030] Growth performance was statistically analyzed at 28 days of age. Subsequently, the abdominal fat tissue was collected after slaughter, its weight was measured, and the abdominal fat rate was calculated. The results showed (see Table 1) that gavage with non-lactolytic Streptococcus CCUG41503 had no effect on the body weight, average daily feed intake, average daily weight gain, and feed conversion rate of broilers at 1-14 days of age, 14-28 days of age, and 1-28 days of age, but reduced the abdominal fat rate of broilers at 28 days of age, and the abdominal fat tissue was significantly thinned, and the diameter and area of fat cells were significantly reduced (see Figure 1 ).

[0031] Table 1 Effects of gavage with non-lactolytic Streptococcus CCUG41503 on the growth performance of broilers

[0032]

[0033]

[0034] Example 2

[0035] Effects of gavage with non-lactolytic Streptococcus CCUG41503 on obese mice.

[0036] The 7-week-old germ-free C57BL / 6J male mice used in the experiment were sourced from Chengdu Bosa Experimental Animal Co., Ltd. Before the formal experiment began, all mice were fed a standard diet for 1 week. Forty-eight C57BL / 6J male mice were randomly divided into 3 groups (n = 16). Among them, the control group (CON) was fed a normal diet, and the high-fat group (HFD) and the bacterial solution gavage group (HFD + SA) were fed a 60% high-fat diet.

[0037] The HFD + SA group was gavaged with 0.2 mL of non-lactolytic Streptococcus CCUG41503 at a dose of 1×10 8 CFU / mL every day. The CON group and the HFD group were gavaged with an equal amount of PBS. The treatment by gavage lasted for 7 weeks. During this period, the individual body weight and feed intake were measured weekly.

[0038] After the experiment ended, serum was obtained by centrifuging the blood from the orbital venous plexus of the mice. Subsequently, the mice were dissected, and the epididymal white adipose tissue was collected, weighed, and the fat rate was calculated.

[0039] The results showed that gavage with non-lactolytic Streptococcus CCUG41503 had no effect on the average feed intake of obese mice, but significantly reduced the body weight of obese mice and the contents of total cholesterol and triglycerides in the serum (see Figure 2)。In addition, intragastric administration of Streptococcus lactolyticus CCUG41503 also significantly reduced the content of epididymal white adipose tissue in obese mice, and the diameter and area of adipocytes were significantly reduced (see Figure 3 ).

[0040] Obviously, the above-mentioned embodiments of the present invention are merely examples for clearly illustrating the present invention, rather than limiting the implementation manners of the present invention. For those of ordinary skill in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all implementation manners here. Any modifications, equivalent replacements, and improvements made within the spirit and principle of the present invention shall be included in the protection scope of the claims of the present invention.

Claims

1. Application of non-lactolytic Streptococcus in the preparation of products for preventing obesity.

2. The use according to claim 1, characterized in that: The non-lactolytic streptococcus reduces abdominal fat rate, body weight and the content of total cholesterol and triglyceride in serum, thereby playing the role of reducing fat and preventing obesity.

3. A product for preventing obesity, characterized in that: Including non-lactolytic Streptococcus.

Images